Sarepta Therapeutics (SRPT) Non-Current Assets (2010 - 2026)

Sarepta Therapeutics has reported Non-Current Assets for 17 years, with the latest figure at $869.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 15.86% year-over-year to $869.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 billion (down 2.88% YoY), and the FY2025 full-year result was $811.8 million, down 8.76% from the prior year.
• Non-Current Assets for Q1 2026 stood at $869.1 million, up from $811.8 million in the prior quarter.
• The five-year high for Non-Current Assets was $1.0 billion in Q1 2025, with the low at $525.2 million in Q1 2022.
• Average Non-Current Assets over 5 years is $737.3 million, with a median of $740.6 million recorded in 2024.
• Year-over-year, Non-Current Assets jumped 38.81% in 2024 and decreased 15.86% in 2026.
• Tracing SRPT's Non-Current Assets over 5 years: stood at $570.5 million in 2022, then climbed by 20.11% to $685.2 million in 2023, then gained by 29.84% to $889.7 million in 2024, then fell by 8.76% to $811.8 million in 2025, then advanced by 7.06% to $869.1 million in 2026.
• The last three Non-Current Assets figures came in at $869.1 million (Q1 2026), $811.8 million (Q4 2025), and $771.1 million (Q3 2025), per Business Quant data.

Peer Comparison